Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects
NCT ID: NCT01675167
Last Updated: 2017-02-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
815 participants
INTERVENTIONAL
2012-09-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects
NCT01633944
Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain
NCT01256450
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
NCT01871285
Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain
NCT00941304
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.
NCT00315874
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Buccal Film
Twice Daily Dosing
Placebo
Matching Placebo Buccal Film twice daily
Buprenorphine HCl Buccal Film
Twice Daily Dosing
Buprenorphine
Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Buprenorphine
Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
Placebo
Matching Placebo Buccal Film twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treating CLBP with a stable daily maintenance dose of ATC opioid analgesic medication equivalent to ≥30 mg and ≤160 mg morphine sulfate equivalents (MSE) per day for ≥4 weeks. (Additional as needed \[PRN\] analgesic rescue medications permitted on top of the stable daily maintenance dose of ≥30 mg MSE opioid analgesic, but must be included in the total daily MSE calculation and in combination with the stable daily maintenance dose not to exceed 160 mg MSE per day)
* Stable health, as determine by Principal Investigator
* Females are practicing abstinence, using a medically acceptable form of contraception, or post-menopausal, biologically sterile, or surgically sterile for more than 1 year
* Willing and able to comply with all protocol required visits and assessments
Exclusion Criteria
* Subjects with history of other chronic painful conditions
* Reflex sympathetic dystrophy or causalgia, acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis
* Allergy or contraindications of any opioid or acetaminophen
* Surgical procedure for relief of pain within 6 months
* Hypokalemia or clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia
* QT interval corrected using Fridericia's formula (QTcF) of ≥450 milliseconds on the 12-lead electrocardiogram (ECG)
* History of long QT syndrome or a family member with this condition
* Moderate to severe hepatic impairment
* Moderate to severe renal impairment
* Current or past history of alcohol abuse
* Positive urine toxicology screen for drug of abuse
* History or abnormalities on physical exam, vital signs, electrocardiogram, or laboratory values
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioDelivery Sciences International
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Finn, PharmD
Role: STUDY_DIRECTOR
BioDelivery Sciences International, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parkway Medical Center
Birmingham, Alabama, United States
Haleyville Clinical Research LLC
Haleyville, Alabama, United States
Horizon Research Group. Inc / Alabama Orthopedice
Mobile, Alabama, United States
Arizona Research Center
Phoenix, Arizona, United States
Global Research
Anaheim, California, United States
Catalina Research Institute, LLC
Chino, California, United States
Synergy Clinical Research Center of Escondido
Escondido, California, United States
RX Clinical Research, Inc.
Garden Grove, California, United States
Adam D. Karns, MD
Los Angeles, California, United States
Stamford Therapeutics Consortium
Stamford, Connecticut, United States
Century Clinic Research
Daytona Beach, Florida, United States
Avail Clinical Research, LLC
DeLand, Florida, United States
Florida Health Center
Fort Lauderdale, Florida, United States
Eastern Research, Inc.
Hialeah, Florida, United States
Florida Institute of Medical Research
Jacksonville, Florida, United States
Drug Study Institute
Jupiter, Florida, United States
Health Awareness, Inc.
Jupiter, Florida, United States
FPA Clinical Research
Kissimmee, Florida, United States
Try Research, Inc.
Maitland, Florida, United States
NEMA Research, Inc.
Naples, Florida, United States
Compass Research, LLC
Orlando, Florida, United States
Peninsula Research, Inc.
Ormond Beach, Florida, United States
Gold Coast Research, LLC
Plantation, Florida, United States
Progressive Medical Research
Port Orange, Florida, United States
Clinical Research of West Florida, Inc.
Tampa, Florida, United States
Palm Beach Research Center
West Palm Beach, Florida, United States
National Pain Research Institute, LLC
Winter Park, Florida, United States
Atlanta Research Center
Atlanta, Georgia, United States
River Birch Research Alliance, LLC
Blue Ridge, Georgia, United States
Drug Studies America
Marietta, Georgia, United States
Georgia Institute for Clinical Research, LLC
Marietta, Georgia, United States
Taylor Research, LLC
Marietta, Georgia, United States
Georgia Pain & Spine Care & Better Health Clinical Research
Newnan, Georgia, United States
Clinical Investigations Specialists, Inc.
Gurnee, Illinois, United States
MediSphere Medical Research, LLC
Evansville, Indiana, United States
Integrated Clinical Trial Services, Inc
West Des Moines, Iowa, United States
International Clinical Research Institute, Inc.
Overland Park, Kansas, United States
Willis-Kinghton Physician Network / River Cities International Pain Specialist
Bossier City, Louisiana, United States
Clinical Trials Management, LLC
Metairie, Louisiana, United States
Best Clinical Trials, LLC
New Orleans, Louisiana, United States
River Cities Clinical Research Center
Shreveport, Louisiana, United States
MedVadis Research Corp.
Watertown, Massachusetts, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
The Center for Clinical Trials
Biloxi, Mississippi, United States
Office of Robert Kaplan, DO
Las Vegas, Nevada, United States
Comprehensive Clinical Research
Berlin, New Jersey, United States
Long Island Gastrointestinal Research Group
Great Neck, New York, United States
Upstate Clinical Research Associates
Williamsville, New York, United States
PharmQuest, LLC
Greensboro, North Carolina, United States
The Center for Clinical Research
Winston-Salem, North Carolina, United States
Plains Medical Clinic, LLC
Fargo, North Dakota, United States
Clinical Inquest Center, Ltd
Beavercreek, Ohio, United States
New Horizons Health Research
Cincinnati, Ohio, United States
Prestige Clinical Research
Franklin, Ohio, United States
Health Research Institute
Oklahoma City, Oklahoma, United States
Neuropsychiatric Research Center Research
Oklahoma City, Oklahoma, United States
Brandywine Clinical Research
Downingtown, Pennsylvania, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Health Concepts
Rapid City, South Dakota, United States
FutureSearch Clinical Trials
Austin, Texas, United States
KRK Medical Research
Dallas, Texas, United States
Future Search Trials of Dallas, LP
Dallas, Texas, United States
Advanced Clinical Research of Houston
Houston, Texas, United States
Clinical Trial Network
Houston, Texas, United States
Innovative Clinical Trials
San Antonio, Texas, United States
Highland Clinical Research
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EN3409-307
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.